Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
 Announces Annual Meeting of Stockholders - EconoTimes)
SHANGHAI, China and CUPERTINO, Calif., March 21, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 28, 2017. The meeting will be held at the Company’s office at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California 95014 at 9:00 a.m. PDT. Stockholders of record as of March 10, 2017, the record date for the meeting, are authorized and asked to vote in the manner directed in the proxy materials.
A stockholder, once having received his/her proxy notice and access card, may view the proxy statement and related materials online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59 p.m., Thursday, April 27, 2017, EDT. If your shares are held in the name of a bank, broker or other nominee, please check with your bank, broker or nominee and follow the voting instructions it provides. Please send an email to [email protected] if you have questions about the Annual Meeting or have not received your proxy notice card by post or by email.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 [email protected] Vivian Chen Managing Director Investor Relations, Citigate Dewe Rogerson +1 347 481-3711 [email protected]
